| David Daining, MD | |
|
405 Monroe St, Pella, IA 50219-1189 | |
| (641) 628-3832 | |
| (641) 628-8901 |
| Full Name | David Daining |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 405 Monroe St, Pella, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578675153 | NPI | - | NPPES |
| 1027649 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 24609 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| David Daining, MD 405 Monroe St, Pella, IA 50219-1189 Ph: (641) 628-3832 | David Daining, MD 405 Monroe St, Pella, IA 50219-1189 Ph: (641) 628-3832 |
News Archive
A systematic review of research into the use of nutritional supplements for the treatment of anxiety disorders has found strong evidence for the use of extracts of passionflower or kava and combinations of L-lysine and L-arginine. Researchers writing in BioMed Central's open access Nutrition Journal pooled the results of 24 studies involving a total of more than 2000 participants, showing that some nutritional and herbal supplements can be effective, without the risk of serious side effects.
In an unprecedented effort to bring prevention of chronic diseases to the top of the EU agenda, the MEP Heart Group , the MEP Group for Kidney Health , the EU Diabetes Working Group and MEPs Against Cancer organise a joint meeting today in the European Parliament, together with representatives of health professionals and health activists at European level.
Keryx Biopharmaceuticals reported today the randomization of the last patient in its short-term study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.
Sangamo BioSciences, Inc. announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis."
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
› Verified 3 days ago
Dale Vander Broek, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 2 Deer Run Dr, Pella, IA 50219 Phone: 641-780-1202 | |
Mrs. Ruth Kernyuy Bame Mome, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 405 Monroe St, Pella, IA 50219 Phone: 641-628-6610 | |
Dr. Ronald R. Childerston, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 405 Monroe St, Pella, IA 50219 Phone: 641-621-2200 Fax: 641-621-2335 | |
Dr. Shelby Dames, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 405 Monroe St, Pella, IA 50219 Phone: 641-620-2021 Fax: 641-620-2020 | |
Dr. Don Xuan Nguyen, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 404 Jefferson St, Pella, IA 50219 Phone: 641-628-6610 Fax: 641-620-5593 | |
Dr. Stewart Douglas Kanis, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 405 Monroe St, Pella, IA 50219 Phone: 641-628-3832 Fax: 641-628-8894 |